Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Investigation of drug product and container-closure interactions: A case study of diluent containing prefilled syringe.

Thakare V, Mayr B, Artenjak A, Nianios D, Sest M, Müller M, Maltsev OV, Nowicki K, Mischo A, Ehrenstrasser C, Fink M, Thanhaeuser S, Cerreti A.

Eur J Pharm Biopharm. 2019 Jul;140:67-77. doi: 10.1016/j.ejpb.2019.04.018. Epub 2019 Apr 30.

PMID:
31051250
2.

Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.

Bihr S, Ohashi R, Moore AL, Rüschoff JH, Beisel C, Hermanns T, Mischo A, Corrò C, Beyer J, Beerenwinkel N, Moch H, Schraml P.

Neoplasia. 2019 Feb;21(2):247-256. doi: 10.1016/j.neo.2018.12.006. Epub 2019 Jan 16.

3.

Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study.

Samaras P, Rütti MF, Seifert B, Bachmann H, Schanz U, Eisenring M, Renner C, Susanne Müller AM, Schmidt A, Mischo A, Fuchs I, Bargetzi M, Manz MG, Stupp R, Petrausch U, Stenner-Liewen F.

Biol Blood Marrow Transplant. 2018 Apr;24(4):694-699. doi: 10.1016/j.bbmt.2017.12.775. Epub 2017 Dec 12.

4.

Neue und vielversprechende molekulare Therapieoptionen in verschiedenen Subtypen des Nierenzellkarzinoms.

Rupp NJ, Mischo A, Moch H.

Ther Umsch. 2017 Sep;74(4):171-179. doi: 10.1024/0040-5930/a000901. Review. German. No abstract available.

PMID:
28950771
5.

Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse.

Gössi F, Spahn M, Zweifel M, Panagiotis S, Mischo A, Stenner F, Hess U, Berthold D, Bargetzi M, Schardt J, Pabst T.

Bone Marrow Transplant. 2017 Feb;52(2):334-336. doi: 10.1038/bmt.2016.285. Epub 2016 Nov 28. No abstract available.

PMID:
27892951
6.

MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients.

Lukamowicz-Rajska M, Mittmann C, Prummer M, Zhong Q, Bedke J, Hennenlotter J, Stenzl A, Mischo A, Bihr S, Schmidinger M, Vogl U, Blume I, Karlo C, Schraml P, Moch H.

Oncotarget. 2016 Nov 29;7(48):78433-78447. doi: 10.18632/oncotarget.12618.

7.

Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance.

Razafinjatovo C, Bihr S, Mischo A, Vogl U, Schmidinger M, Moch H, Schraml P.

BMC Cancer. 2016 Aug 17;16:638. doi: 10.1186/s12885-016-2688-0.

8.

Pentraxin 3 is an anti-inflammatory protein associated with lipid-induced interleukin 10 in vitro.

Slusher AL, Mischo AB, Acevedo EO.

Cytokine. 2016 Oct;86:36-40. doi: 10.1016/j.cyto.2016.07.012. Epub 2016 Jul 22.

PMID:
27450429
9.

Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients.

Maul JT, Stenner-Liewen F, Seifert B, Pfrommer S, Petrausch U, Kiessling MK, Schanz U, Nair G, Mischo A, Taverna C, Schmidt A, Bargetzi M, Stupp R, Renner C, Samaras P.

J Clin Apher. 2017 Feb;32(1):21-26. doi: 10.1002/jca.21459. Epub 2016 Mar 22.

PMID:
27001243
10.

Oncotargets in different renal cancer subtypes.

Moch H, Montironi R, Lopez-Beltran A, Cheng L, Mischo A.

Curr Drug Targets. 2015;16(2):125-35. Review.

PMID:
25619751
11.

Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.

Samaras P, Pfrommer S, Seifert B, Petrausch U, Mischo A, Schmidt A, Schanz U, Nair G, Bargetzi M, Taverna C, Stupp R, Stenner-Liewen F, Renner C.

Biol Blood Marrow Transplant. 2015 Jan;21(1):74-80. doi: 10.1016/j.bbmt.2014.09.020. Epub 2014 Sep 30.

12.

Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.

Jakka G, Schuberth PC, Thiel M, Held G, Stenner F, Van Den Broek M, Renner C, Mischo A, Petrausch U.

Anticancer Res. 2013 Oct;33(10):4189-201.

PMID:
24122982
13.

Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.

Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, Soltermann A, Jüngel A, Marroquin Belaunzaran O, Stahel R, Renner C, Petrausch U.

J Transl Med. 2013 Aug 12;11:187. doi: 10.1186/1479-5876-11-187.

14.

RP1 is a phosphorylation target of CK2 and is involved in cell adhesion.

Stenner F, Liewen H, Göttig S, Henschler R, Markuly N, Kleber S, Faust M, Mischo A, Bauer S, Zweifel M, Knuth A, Renner C, Wadle A.

PLoS One. 2013 Jul 3;8(7):e67595. doi: 10.1371/journal.pone.0067595. Print 2013.

15.

Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation.

Samaras P, Zardavas D, Petrausch U, Buset EM, Haile SR, Honegger H, Siciliano RD, Schanz U, Mischo A, Schäfer NG, Taverna C, Knuth A, Stahel R, Renner C, Stenner-Liewen F.

Swiss Med Wkly. 2013 May 7;143:w13791. doi: 10.4414/smw.2013.13791. eCollection 2013. No abstract available.

16.

Structural insights into a wildtype domain of the oncoprotein E6 and its interaction with a PDZ domain.

Mischo A, Ohlenschläger O, Hortschansky P, Ramachandran R, Görlach M.

PLoS One. 2013 Apr 30;8(4):e62584. doi: 10.1371/journal.pone.0062584. Print 2013.

17.

Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.

Schuberth PC, Jakka G, Jensen SM, Wadle A, Gautschi F, Haley D, Haile S, Mischo A, Held G, Thiel M, Tinguely M, Bifulco CB, Fox BA, Renner C, Petrausch U.

Gene Ther. 2013 Apr;20(4):386-95. doi: 10.1038/gt.2012.48. Epub 2012 Jun 28.

PMID:
22739387
18.

Recombinant production of isotope-labeled peptides and spontaneous cyclization of amino-terminal glutamine into pyroglutamic acid.

Mischo A, Ohlenschläger O, Gührs KH, Görlach M.

Chembiochem. 2012 Jul 9;13(10):1421-3. doi: 10.1002/cbic.201200178. Epub 2012 May 22. No abstract available.

PMID:
22619187
19.

Structurally diverse μ-conotoxin PIIIA isomers block sodium channel NaV 1.4.

Tietze AA, Tietze D, Ohlenschläger O, Leipold E, Ullrich F, Kühl T, Mischo A, Buntkowsky G, Görlach M, Heinemann SH, Imhof D.

Angew Chem Int Ed Engl. 2012 Apr 23;51(17):4058-61. doi: 10.1002/anie.201107011. Epub 2012 Mar 12. Review. No abstract available.

PMID:
22407516
20.

NMR assignment of a PDZ domain in complex with a HPV51 E6 derived N-terminally pyroglutamic acid modified peptide.

Mischo A, Ohlenschläger O, Ramachandran R, Görlach M.

Biomol NMR Assign. 2013 Apr;7(1):47-9. doi: 10.1007/s12104-012-9374-1. Epub 2012 Mar 6.

PMID:
22392342
21.

[After care in Hodgkin lymphoma].

Petrausch U, Samaras P, Mischo A, Stenner F, Tinguely M, Schäfer N, Studer G, Renner C.

Praxis (Bern 1994). 2011 Dec 14;100(25):1515-20; quiz 1521-2. doi: 10.1024/1661-8157/a000744. German. No abstract available.

PMID:
22161876
22.

Autologous stem cell transplantation: leukapheresis product has anti-angiogenic effects in vivo correlating with neutrophil-derived VEGFR1.

Luethy A, Stenner F, Lohri C, Muller C, Samaras P, Steiner R, Van Den Broek M, Mischo A, Renner C, Knuth A, Ruegg C, Wenger RH, Zweifel M.

Anticancer Res. 2011 Oct;31(10):3115-24.

PMID:
21965716
23.

Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience.

Samaras P, Blickenstorfer M, Haile SR, Siciliano RD, Petrausch U, Mischo A, Zweifel M, Honegger H, Schanz U, Stussi G, Taverna C, Bauer S, Knuth A, Stenner-Liewen F, Renner C.

Swiss Med Wkly. 2011 May 31;141:w13203. doi: 10.4414/smw.2011.13203. eCollection 2011.

24.

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis.

Mischo A, Bubel N, Cebon JS, Samaras P, Petrausch U, Stenner-Liewen F, Schaefer NG, Kubuschok B, Renner C, Wadle A.

Int J Oncol. 2011 Jul;39(1):287-94. doi: 10.3892/ijo.2011.1032. Epub 2011 May 6.

PMID:
21573493
25.

Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.

Samaras P, Buset EM, Siciliano RD, Haile SR, Petrausch U, Mischo A, Honegger H, Pestalozzi BC, Schanz U, Stussi G, Stahel RA, Knuth A, Renner C, Stenner-Liewen F.

Oncology. 2010;79(1-2):93-7. doi: 10.1159/000320604. Epub 2010 Nov 15.

26.

Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.

Samaras P, Blickenstorfer M, Siciliano RD, Haile SR, Buset EM, Petrausch U, Mischo A, Honegger H, Schanz U, Stussi G, Stahel RA, Knuth A, Stenner-Liewen F, Renner C.

Ann Hematol. 2011 Jan;90(1):89-94. doi: 10.1007/s00277-010-1036-8. Epub 2010 Aug 13.

PMID:
20706722
27.

NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses.

Wadle A, Mischo A, Strahl S, Nishikawa H, Held G, Neumann F, Wullner B, Fischer E, Kleber S, Karbach J, Jager E, Shiku H, Odunsi K, Shrikant PA, Knuth A, Cerundolo V, Renner C.

Yeast. 2010 Nov;27(11):919-31. doi: 10.1002/yea.1796.

28.

Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.

Samaras P, Heider H, Haile SR, Petrausch U, Schaefer NG, Siciliano RD, Meisel A, Mischo A, Zweifel M, Knuth A, Stenner-Liewen F, Renner C.

Ann Hematol. 2010 Aug;89(8):783-7. doi: 10.1007/s00277-010-0926-0. Epub 2010 Mar 5.

PMID:
20204361
29.

Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy.

Petrausch U, Samaras P, Haile SR, Veit-Haibach P, Soyka JD, Knuth A, Hany TF, Mischo A, Renner C, Schäefer NG.

Ann Oncol. 2010 Aug;21(8):1694-8. doi: 10.1093/annonc/mdq015. Epub 2010 Feb 5.

30.

Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?

Petrausch U, Samaras P, Veit-Haibach P, Tschopp A, Soyka JD, Knuth A, Hany TF, Mischo A, Renner C, Schaefer NG.

Ann Oncol. 2010 May;21(5):1053-7. doi: 10.1093/annonc/mdp519. Epub 2009 Nov 13.

31.

Regulating functional cell fates in CD8 T cells.

Shrikant PA, Rao R, Li Q, Kesterson J, Eppolito C, Mischo A, Singhal P.

Immunol Res. 2010 Mar;46(1-3):12-22. doi: 10.1007/s12026-009-8130-9. Review.

32.

Characterizing host immune responses by monitoring fluorescently marked cells.

Mischo A, Eppolito C, Li Q, Shrikant PA.

Immunol Invest. 2007;36(5-6):791-805. No abstract available.

PMID:
18161529
33.

Serological immune response to cancer testis antigens in patients with pancreatic cancer.

Wadle A, Kubuschok B, Imig J, Wuellner B, Wittig C, Zwick C, Mischo A, Waetzig K, Romeike BF, Lindemann W, Schilling M, Pfreundschuh M, Renner C.

Int J Cancer. 2006 Jul 1;119(1):117-25.

34.

Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer.

Mischo A, Kubuschok B, Ertan K, Preuss KD, Romeike B, Regitz E, Schormann C, de Bruijn D, Wadle A, Neumann F, Schmidt W, Renner C, Pfreundschuh M.

Int J Cancer. 2006 Feb 1;118(3):696-703.

35.

Characterization of Hap/BAG-1 variants as RP1 binding proteins with antiapoptotic activity.

Wadle A, Mischo A, Henrich PP, Stenner-Liewen F, Scherer C, Imig J, Petersen G, Pfreundschuh M, Renner C.

Int J Cancer. 2005 Dec 20;117(6):896-904. Erratum in: Int J Cancer. 2007 Sep 15;121(6):1399. Stenner-Lieven, Frank [corrected to Stenner-Liewen, Frank].

36.

Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library.

Wadle A, Mischo A, Imig J, Wüllner B, Hensel D, Wätzig K, Neumann F, Kubuschok B, Schmidt W, Old LJ, Pfreundschuh M, Renner C.

Int J Cancer. 2005 Oct 20;117(1):104-13.

37.

Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.

Neumann F, Wagner C, Stevanovic S, Kubuschok B, Schormann C, Mischo A, Ertan K, Schmidt W, Pfreundschuh M.

Int J Cancer. 2004 Nov 20;112(4):661-8.

38.

Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.

Wagner C, Neumann F, Kubuschok B, Regitz E, Mischo A, Stevanovic S, Friedrich M, Schmidt W, Rammensee HG, Pfreundschuh M.

Cancer Immun. 2003 Dec 17;3:18.

39.

Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients.

Mischo A, Wadle A, Wätzig K, Jäger D, Stockert E, Santiago D, Ritter G, Regitz E, Jäger E, Knuth A, Old L, Pfreundschuh M, Renner C.

Cancer Immun. 2003 Jun 27;3:5.

40.

Chromosomal localization and promoter analysis of the adenomatous polyposis coli binding protein RP1.

Wadle A, Thiel G, Mischo A, Jung V, Pfreundschuh M, Renner C.

Oncogene. 2001 Sep 13;20(41):5920-9.

41.

EB/RP gene family encodes tubulin binding proteins.

Juwana JP, Henderikx P, Mischo A, Wadle A, Fadle N, Gerlach K, Arends JW, Hoogenboom H, Pfreundschuh M, Renner C.

Int J Cancer. 1999 Apr 12;81(2):275-84.

Supplemental Content

Loading ...
Support Center